Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies

Trial Profile

A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Dec 2018 Planned End Date changed from 4 Sep 2021 to 2 Oct 2021.
    • 09 Dec 2018 Planned primary completion date changed from 4 Sep 2020 to 2 Oct 2020.
    • 16 Oct 2018 Planned number of patients changed from 108 to 80.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top